References
- Verna EC, Brown RS. Hepatitis C virus and liver trans-plantation. Clin Liver Dis 2006; 10: 919–40.
- Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006; 6: 449–58.
- Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guidelines, diagnosis, management and treatment of he-patitisC. Hepatology 2004; 39: 1147–71.
- Peck-Radosavlajevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegy-lated interferon-. Gastroenterology 2002; 123: 141–151.
- Schmid M, Kreil A, Jessner W, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with dif-ferent interferon mono and combination therapy. Gut 2005; 54; 1014–1020.
- De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hep-atitis C virus infection: role of membrane oxidative damage. He-patology 2000; 31: 997–1004.
- Aman MJ, Keller U, Derigs G, Mohamadzadech M, Huber C, and Peschel C. Regulation of cytokine expression by inter-feron- in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 re-ceptor antagonist. Blood. 1994; 84: 4142-50.
- Tarumi T, Sawada K, Sato N, et al. Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 1995; 23: 1310–8.
- Wang Q, Miyakawa Y, Fox N, and Kaushansky K. Inter-feron- directly represses megakaryopoiesis by inhibiting throm-bopoietin-induced signalling through induction of SOCS-1. Blood 2000; 96: 2093-2099.
- Gomez-Rangel JD, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide. Am J Hematol 2003; 74: 290–291.
- Tefferi A, Elliott MA, Yoon S, et al. Clinical and bone mar-row effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001; 97: 1896.
- Nguyen MH, Keeffe EB. Prevalence and treatment of HCV genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3 (Suppl 2):S97–S101.
- Bonny C, Fontaine H, Poynard T, et al. Effectiveness of interferon plus RBV combination in the treatment of naive pa-tients with hepatitis C virus type 5. A French multicentre retro-spective study [Abstract]. Aliment Pharmacol Ther 2006; 24: 593–600.
- Legrand-Abravanel F, Sandres-Saune K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon- plus ribavirin. JID 2004; 189: 1397-1400.
- Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicen-tre histological and clinical study. Br J Haematol 2000; 108: 64–71.